403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Woman With Motor Neuron Disease Speaks Freely Via Brain Implant
(MENAFN) A Michigan woman living with a progressive motor neuron disease has become the first person to generate her own original speech using an experimental brain-computer interface, US neurotechnology firm Paradromics announced Monday — a milestone the company says marks a leap beyond earlier trials that relied on pre-scripted sentences.
The woman, in her 60s, is the inaugural participant in Paradromics' Connect-One Early Feasibility Study, receiving the company's Connexus implant. Where prior demonstrations had participants repeat sentences chosen in advance by researchers, this trial allowed her to freely choose her own words. The system captured neural signals tied to her intended speech and converted them into both text and a real-time synthesized voice.
The moment the free-speech mode switched on, her first self-selected sentence was: "Okay, I have a lot to say." Paradromics confirmed the system decoded it flawlessly, with zero errors.
In that same session, she used the interface to hold a live phone conversation with her grandchildren, posing questions and responding aloud through the device's generated voice.
"She determines what she wants to say, and the system enables her to say it," said Matt Angle, founder and CEO of Paradromics.
The participant lives with severe dysarthria, a disorder that severely impairs clarity of speech. While her husband can generally understand her, the company said communicating with others has grown steadily harder. She retains some natural speaking ability despite the condition.
Asked by University of Michigan Health neurosurgeon Matthew Willsey what she'd tell someone weighing whether to undergo the implant surgery, she used the device to answer — encouraging them not to be afraid, and describing the chance to help others through the research as a rewarding one. Paradromics said every word she intended to convey was decoded with complete accuracy.
Willsey called the achievement a landmark step toward giving people with speech-limiting conditions the ability to communicate freely using a fully implanted system.
Technically, the Connexus device relies on 421 microelectrodes that capture signals from individual neurons. Per University of Michigan Health, those signals route to a compact transceiver implanted in the chest, which then transmits wirelessly through unbroken skin to an external receiver and computer.
Beyond real-time communication, researchers are tracking how her neural patterns shift as she listens to language, prepares to speak, attempts speech, and silently forms language in her mind. Paradromics reported distinguishing separate neural signatures for attempted speech — the deliberate effort to produce words — versus imagined speech, in which language is generated internally without any physical attempt to speak.
The company was careful to note the findings do not suggest the device can passively decode unprompted thoughts; the data reflects language she consciously and deliberately generated during controlled research tasks.
She received the Connexus implant in June at University of Michigan Health and will remain under observation for six years as researchers track the device's long-term safety, durability, and its capacity to restore communication and support computer control.
The FDA granted Paradromics an Investigational Device Exemption for the trial in November 2025 — authorization that permits human testing of the experimental device but stops short of approval for commercial or general use. The study spans three sites: University of Michigan Health, UC Davis Health, and Mass General Brigham Neuroscience Institute.
Because this result comes from just the trial's first participant, the findings remain preliminary. Paradromics has not pointed to a peer-reviewed publication backing the announcement, and researchers say data from additional participants over a longer timeframe will be needed to determine how safe, consistent, and useful the system proves outside tightly controlled research settings.
The woman, in her 60s, is the inaugural participant in Paradromics' Connect-One Early Feasibility Study, receiving the company's Connexus implant. Where prior demonstrations had participants repeat sentences chosen in advance by researchers, this trial allowed her to freely choose her own words. The system captured neural signals tied to her intended speech and converted them into both text and a real-time synthesized voice.
The moment the free-speech mode switched on, her first self-selected sentence was: "Okay, I have a lot to say." Paradromics confirmed the system decoded it flawlessly, with zero errors.
In that same session, she used the interface to hold a live phone conversation with her grandchildren, posing questions and responding aloud through the device's generated voice.
"She determines what she wants to say, and the system enables her to say it," said Matt Angle, founder and CEO of Paradromics.
The participant lives with severe dysarthria, a disorder that severely impairs clarity of speech. While her husband can generally understand her, the company said communicating with others has grown steadily harder. She retains some natural speaking ability despite the condition.
Asked by University of Michigan Health neurosurgeon Matthew Willsey what she'd tell someone weighing whether to undergo the implant surgery, she used the device to answer — encouraging them not to be afraid, and describing the chance to help others through the research as a rewarding one. Paradromics said every word she intended to convey was decoded with complete accuracy.
Willsey called the achievement a landmark step toward giving people with speech-limiting conditions the ability to communicate freely using a fully implanted system.
Technically, the Connexus device relies on 421 microelectrodes that capture signals from individual neurons. Per University of Michigan Health, those signals route to a compact transceiver implanted in the chest, which then transmits wirelessly through unbroken skin to an external receiver and computer.
Beyond real-time communication, researchers are tracking how her neural patterns shift as she listens to language, prepares to speak, attempts speech, and silently forms language in her mind. Paradromics reported distinguishing separate neural signatures for attempted speech — the deliberate effort to produce words — versus imagined speech, in which language is generated internally without any physical attempt to speak.
The company was careful to note the findings do not suggest the device can passively decode unprompted thoughts; the data reflects language she consciously and deliberately generated during controlled research tasks.
She received the Connexus implant in June at University of Michigan Health and will remain under observation for six years as researchers track the device's long-term safety, durability, and its capacity to restore communication and support computer control.
The FDA granted Paradromics an Investigational Device Exemption for the trial in November 2025 — authorization that permits human testing of the experimental device but stops short of approval for commercial or general use. The study spans three sites: University of Michigan Health, UC Davis Health, and Mass General Brigham Neuroscience Institute.
Because this result comes from just the trial's first participant, the findings remain preliminary. Paradromics has not pointed to a peer-reviewed publication backing the announcement, and researchers say data from additional participants over a longer timeframe will be needed to determine how safe, consistent, and useful the system proves outside tightly controlled research settings.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment